Amyotrophic Lateral Sclerosis (ALS)

Official Title

Study Summary

This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include three components: a Single-Ascending-Dose (SAD) stage, a Multiple-Ascending-Dose (MAD) stage, and an Open-Label Safety Expansion (OSE) stage.

Eligibility and Recruitment Information

Recruitment Status	Recruiting
Eligible Genders	Both
Eligible Ages	18+
Inclusion	ALS Diagnosis
Exclusion	ALS Diagnosis
Start Date
Compensation	Variable
Location	Orlando, FL

Study Information

Condition	Amyotrophic Lateral Sclerosis (ALS)
Study Phase	Phase 1

Administrative Information

Study ID	NEUROLOGICAL
Investigators	Ira Goodman, MD

Apply for this study

First Name *

Please include your first name.

Last Name *

Please include your last name.

Email *

Please include a valid email address.

Phone

How did you hear about us?

Comments

Thank you for applying.

Sorry, something wen't wrong. Please contact us for support.